Latest / Decera Clinical Education Oncology Podcast
TROP2-Directed ADCs in NSCLC: Current Evidence, Emerging Therapies, and Future Treatment Strategies
In this podcast episode, Christine M. Bestvina, MD, and Joshua E. Reuss, MD, discuss the current and emerging role of TROP2-directed ADCs in NSCLC, including:
Current clinical use of Dato-DXd in previously treated EGFR-mutated NSCLC, including evidence from TROPION-Lung01 and TROPION-Lung05 and considerations for treatment sequencing
Emerging efficacy data for investigational TROP2 ADCs, including sacituzumab tirumotecan, and the potential role of these agents in earlier lines of therapy
Ongoing clinical trials evaluating TROP2 ADCs alone and in combination with immunotherapy, chemotherapy…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.